- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02461836
Study of Stereotactic Body Radiation Therapy for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)
An Open-Labeled, Randomized Phase II Trial of Adjuvant Chemotherapy in Combination With Stereotactic Body Radiation Therapy (SBRT) Versus Adjuvant Chemotherapy Alone for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)
Pancreatic cancer is one of the deadliest tumor types of the alimentary system. Resection is the only curable method to treat pancreatic cancer. However, even if radical resection is achieved, the 5-year survival rate is still low because of tumor recurrence. It's reported adjuvant radiation can prolong survival and improve quality of life after surgery. For R0 (microscopic negative margin) resection patients with advanced stages (T3 or N1), the value of adjuvant radiation is still in debate. It's warranted to explore the role of adjuvant radiation for patients after radical resection of pancreatic cancer with advanced stages (T3 or N1) in large, prospective, and randomized cohorts.
The application of Stereotactic Body Radiation Therapy (SBRT) makes radiation less harmful and more flexible. It is hoped that adjuvant SBRT may benefit post-operative patients with advanced stages and one day adjuvant SBRT combined with chemotherapy become the standard of care for pancreatic cancer patients.
Přehled studie
Detailní popis
Pancreatic cancer is one of the deadliest tumor types of the alimentary system. Despite of the dramatic progress of diagnostic methods and surgical technics, the overall 5-year survival is still around 5%. Resection is the only curable method to treat pancreatic cancer, although only a small proportion of patients are eligible for operation. However, even if radical resection is achieved, the 5-year survival rate is only 15-20%. The main cause of death is tumor recurrence, which is as high as 50-70% in 3 years after operation. By now, it is widely accepted that pancreatic cancer is a systemic disease. Systemic treatments are recommended in neoadjuvant and adjuvant manners. It's reported adjuvant radiation can prolong survival and improve quality of life after surgery, especially for patients who undergo a R1 (microscopic positive margin) and R2 (macroscopic positive margin) resection. For R0 (microscopic negative margin) resection patients with advanced stages (T3 or N1), the value of adjuvant radiation is still in debate. Some argues adjuvant radiation after radical resection makes no effect on preventing local recurrence and metastasis but may impair patients' quality of life and overall survival. On the contrary, some other researchers draw the conclusion that adjuvant radiation may facilitate the local control of tumor recurrence in small cohorts. It's warranted to explore the role of adjuvant radiation for patients after radical resection of pancreatic cancer with advanced stages (T3 or N1) in large, prospective, and randomized cohorts.
Traditionally, radiation may take more than one month to deliver and the dosage is restricted to prevent damage to surrounding tissues. The size effects and duration impair patients' compliance. Recently, the application of Stereotactic Body Radiation Therapy (SBRT) makes radiation less harmful and more flexible. The advantages of SBRT are higher dosage of radiation, less damage to surrounding organs, and significant reduce of duration. To our knowledge, there is no big randomized clinical trial to evaluate the value of SBRT for patients after radical resection of pancreatic cancer with advanced stages (T3 or N1). It is hoped that adjuvant SBRT may benefit post-operative patients with advanced stages and one day adjuvant SBRT combined with chemotherapy become the standard of care for pancreatic cancer patients.
Typ studie
Zápis (Očekávaný)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Zhejiang
-
Hangzhou, Zhejiang, Čína, 310009
- Nábor
- The second affiliated hospital of Zhejiang University
-
Kontakt:
- Tao Ma, MD,PhD
- Telefonní číslo: +8613857148997
- E-mail: zjumatao@gmail.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Male/Female subjects, age ≥ 18 years and ≤ 75 years old at the time informed consent is signed
- Pathologically confirmed pancreatic adenocarcinoma or mixed-type pancreatic carcinoma (adenocarcinoma predominantly)
- The operation must be radical resection (R0), with all margins negative.
- Eastern Cooperative Oncology Group (ECOG) score: 0-2
- Without large volume ascites or pleural effusion
Lab tests:
a Complete blood cell count: HGB≥100g/L, WBC≥4×109/L, PLT≥100×109/L b Liver function: Total bilirubin≤3 x upper limit of normal range (ULN) with direct bilirubin within normal range, alanine aminotransferase (ALT) / aspartate aminotransferase (AST)≤3 c Renal function: Creatine≤1.5 x ULN or creatine clearance≥60 ml/min
- Heart and lung function well (Eject function>55%)
- Females of child-bearing potential must demonstrate a negative serum pregnancy test result at screening confirmed by local negative urine pregnancy dipstick within 72 hours prior to the first dose of Gemcitabine.
- At least 30 days from major surgery before randomization, with full recovery
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted
- Able to adhere to the study visit schedule and other protocol requirements
Exclusion Criteria:
- Margin positive resections (R1 or R2)
- Resection of recurrence pancreatic cancer
- Other types of pancreatic cancer (non-adenocarcinoma)
- Subjects with severe complications, can't tolerate chemotherapy in 4-12 weeks after surgery
- Subjects with severe bone marrow suppression
- Subjects with a history of severe lung diseases (interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis), severe liver diseases (active hepatitis, liver cirrhosis), renal dysfunction, uncontrolled diabetes and hypertension, or multiple and severe allergies which may lead to serious complications
- Subjects with severe heart diseases (congested heart failure, systematic coronary disease, uncontrolled arrhythmia, or myocardial infarction in 6 months)
- Under treatment with steroids for a long time
- Subjects with early recurrence of pancreatic cancer before initiation of chemotherapy
- Subjects with diarrhea and infection (body temperature >38.5℃)
- Subjects who was enrolled into another clinical study or finished another clinical study within the previous 4 weeks prior to randomization
- Pregnant or nursing women
- Subjects with other type of malignancies, except of curated basal cell carcinoma and carcinoma in situ of cervix which finished treatments more than half one year ago
- Subjects having any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent them from participating in the study
- Any condition that confounds interpreting data from the study
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Chemo
adjuvant chemotherapy using Gemcitabine for 6 rounds
|
Protocol: Gemcitabine 1000mg/m2.body
surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
Ostatní jména:
|
Experimentální: Chemo+SBRT
SBRT is delivered prior to adjuvant chemotherapy with Gemcitabine for 6 rounds
|
Protocol: Gemcitabine 1000mg/m2.body
surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
Ostatní jména:
Protocol: 5 Gy/d, for 5 consecutive days
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
disease-free survival (DFS)
Časové okno: Up to approximately 36 months
|
Up to approximately 36 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
overall survival (OS)
Časové okno: Up to approximately 60 months
|
Up to approximately 60 months
|
|
quality of life (QOL) as assessed by the EORTC (European Organisation for Research and Treatment of Cancer) QLQ-PAN26 score
Časové okno: Up to approximately 60 months
|
Up to approximately 60 months
|
|
safety as assessed according to NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) Ver. 4
Časové okno: Up to approximately 8 months
|
according to NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) Ver. 4
|
Up to approximately 8 months
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Xueli Bai, MD PHD, Zhejiang University
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Nemoci trávicího systému
- Novotvary
- Novotvary podle místa
- Onemocnění endokrinního systému
- Novotvary trávicího systému
- Novotvary endokrinních žláz
- Onemocnění slinivky břišní
- Novotvary pankreatu
- Fyziologické účinky léků
- Molekulární mechanismy farmakologického působení
- Antiinfekční látky
- Antivirová činidla
- Inhibitory enzymů
- Antimetabolity, Antineoplastika
- Antimetabolity
- Antineoplastická činidla
- Imunosupresivní látky
- Imunologické faktory
- Gemcitabin
Další identifikační čísla studie
- YAN2015-030
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .